EULAR RECOMMENDATIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS – 2013: GENERAL CHARACTERISTICS AND DISPUTABLE PROBLEMS

There has been significant progress in research focused on rheumatoid arthritis (RA) over the past decade. Nine innovative biologics agents – monoclonal antibodies and recombinant proteins inhibiting activity of the key proinflammatory cytokines and pathological activation of T and B cells involved...

Full description

Saved in:
Bibliographic Details
Main Authors: Evgenii Lvovich Nasonov, D E Karateev, N V Chichasova
Format: Article
Language:Russian
Published: IMA PRESS LLC 2014-02-01
Series:Научно-практическая ревматология
Subjects:
Online Access:https://rsp.mediar-press.net/rsp/article/view/1344
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849688902609141760
author Evgenii Lvovich Nasonov
D E Karateev
N V Chichasova
author_facet Evgenii Lvovich Nasonov
D E Karateev
N V Chichasova
author_sort Evgenii Lvovich Nasonov
collection DOAJ
description There has been significant progress in research focused on rheumatoid arthritis (RA) over the past decade. Nine innovative biologics agents – monoclonal antibodies and recombinant proteins inhibiting activity of the key proinflammatory cytokines and pathological activation of T and B cells involved in the development of the immune-inflammatory process – have been designed to treat RA. However, the radical improvement of prognosis in RA patients depends both on launching innovative drugs and refining the treatment strategy. This strategy is based on early diagnosis, which makes it possible to initiate the very early («window of opportunity drug») active and tightly controlled anti-inflammatory therapy aimed at achieving remission as soon as possible (the «Treat to Target» conception). The «Treat to Target» conception formulated by EULAR in 2010 has been widely incorporated in national guidelines on management of RA elaborated in many countries, including Russia. A new edition of EULAR recommendations was prepared in 2013; it has accumulated the scientific progress and clinical experience over the past three years. The publication is aimed at providing the general characteristics of the key provisions in the new recommendations and discussing some disputable problems that have not been solved yet and require further research.
format Article
id doaj-art-e996a722be364da2aa9d5850e9c2c6d9
institution DOAJ
issn 1995-4484
1995-4492
language Russian
publishDate 2014-02-01
publisher IMA PRESS LLC
record_format Article
series Научно-практическая ревматология
spelling doaj-art-e996a722be364da2aa9d5850e9c2c6d92025-08-20T03:21:50ZrusIMA PRESS LLCНаучно-практическая ревматология1995-44841995-44922014-02-015166092210.14412/1995-4484-2013-609-221284EULAR RECOMMENDATIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS – 2013: GENERAL CHARACTERISTICS AND DISPUTABLE PROBLEMSEvgenii Lvovich Nasonov0D E Karateev1N V Chichasova2Nasonova Research Institute of Rheumatology, Russian Academy of Medical Sciences, Moscow, RussiaNasonova Research Institute of Rheumatology, Russian Academy of Medical Sciences, Moscow, RussiaNasonova Research Institute of Rheumatology, Russian Academy of Medical Sciences, Moscow, RussiaThere has been significant progress in research focused on rheumatoid arthritis (RA) over the past decade. Nine innovative biologics agents – monoclonal antibodies and recombinant proteins inhibiting activity of the key proinflammatory cytokines and pathological activation of T and B cells involved in the development of the immune-inflammatory process – have been designed to treat RA. However, the radical improvement of prognosis in RA patients depends both on launching innovative drugs and refining the treatment strategy. This strategy is based on early diagnosis, which makes it possible to initiate the very early («window of opportunity drug») active and tightly controlled anti-inflammatory therapy aimed at achieving remission as soon as possible (the «Treat to Target» conception). The «Treat to Target» conception formulated by EULAR in 2010 has been widely incorporated in national guidelines on management of RA elaborated in many countries, including Russia. A new edition of EULAR recommendations was prepared in 2013; it has accumulated the scientific progress and clinical experience over the past three years. The publication is aimed at providing the general characteristics of the key provisions in the new recommendations and discussing some disputable problems that have not been solved yet and require further research.https://rsp.mediar-press.net/rsp/article/view/1344rheumatoid arthritistreatmenteular recommendations
spellingShingle Evgenii Lvovich Nasonov
D E Karateev
N V Chichasova
EULAR RECOMMENDATIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS – 2013: GENERAL CHARACTERISTICS AND DISPUTABLE PROBLEMS
Научно-практическая ревматология
rheumatoid arthritis
treatment
eular recommendations
title EULAR RECOMMENDATIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS – 2013: GENERAL CHARACTERISTICS AND DISPUTABLE PROBLEMS
title_full EULAR RECOMMENDATIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS – 2013: GENERAL CHARACTERISTICS AND DISPUTABLE PROBLEMS
title_fullStr EULAR RECOMMENDATIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS – 2013: GENERAL CHARACTERISTICS AND DISPUTABLE PROBLEMS
title_full_unstemmed EULAR RECOMMENDATIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS – 2013: GENERAL CHARACTERISTICS AND DISPUTABLE PROBLEMS
title_short EULAR RECOMMENDATIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS – 2013: GENERAL CHARACTERISTICS AND DISPUTABLE PROBLEMS
title_sort eular recommendations for the treatment of rheumatoid arthritis 2013 general characteristics and disputable problems
topic rheumatoid arthritis
treatment
eular recommendations
url https://rsp.mediar-press.net/rsp/article/view/1344
work_keys_str_mv AT evgeniilvovichnasonov eularrecommendationsforthetreatmentofrheumatoidarthritis2013generalcharacteristicsanddisputableproblems
AT dekarateev eularrecommendationsforthetreatmentofrheumatoidarthritis2013generalcharacteristicsanddisputableproblems
AT nvchichasova eularrecommendationsforthetreatmentofrheumatoidarthritis2013generalcharacteristicsanddisputableproblems